PMID- 11578259
OWN - NLM
STAT- MEDLINE
DCOM- 20011025
LR  - 20061115
IS  - 1341-1098 (Print)
IS  - 1341-1098 (Linking)
VI  - 7
IP  - 4
DP  - 2001 Aug
TI  - Relations of the c-myc gene and chromosome 8 in non-small cell lung cancer: 
      analysis by fluorescence in situ hybridization.
PG  - 197-203
AB  - BACKGROUND: Amplification of the c-myc gene has been reported in non-small cell 
      lung cancer (NSCLC). We investigated the c-myc gene amplification and the 
      numerical aberration of chromosome 8 by dual color fluorescence in situ 
      hybridization (FISH) to evaluate the relation between possible genetic 
      abnormalities, pathological factors and prognosis. METHODS: Tumor tissue samples 
      were obtained from 31 patients with NSCLC who underwent lobectomy with 
      mediastinal lymph node dissection. Samples were analyzed by FISH using 8 alpha 
      satellite DNA probe and c-myc gene cosmid probe. The relation between genetic 
      abnormalities, pathological factors (T factor, tumor size, and N factor), and 
      prognostic factors was evaluated by univariate and multivariate analysis, and by 
      the Kaplan-Meier method and log-rank analysis. RESULTS: Chromosome 8 aberrations 
      were T1 (n=3), 44.0%; T2 (n=18), 35.7%; T3 (n=7), 40.0%; T4 (n=3), 39.7% (p=NS). 
      The c-myc gene amplifications were T1, 54.3%; T2, 51.1%; T3, 51.0%; T4, 66.3% 
      (p=NS). There was no difference between patients whose tumor was more than 5 cm 
      (n=16), and 5 cm or less (n=15) in the rate of chromosome 8 aberration (39.3%: 
      36.3%), or the rate of the c-myc gene amplification (52.1%: 53.7%). N factors for 
      chromosome 8 aberrations were N0 (n=18), 35.9%; and N2 (n=11), 44.9% (p=NS). In 
      the c-myc gene amplification, there was a significant difference between N0 and 
      N2 (48.6%, 61.3%, p=0.040). In univariate and multivariate analysis, chromosome 8 
      aberrations correlated with a poor prognosis (p=0.037 and p=0.041). The 5-year 
      survival rate was 15.4% in patients whose rate of chromosome 8 aberrations was 
      40% or more (n=13), which was significantly less than that in patients with an 
      aberration rate of less than 40% (n=19, 57.9%, p=0.014). CONCLUSION: The c-myc 
      gene amplification correlates with lymph node metastasis. Although there was no 
      significant link between the amplification of the c-myc gene and clinical 
      outcome, the numerical chromosome 8 aberrations was considered to be a factor for 
      survival.
FAU - Kubokura, H
AU  - Kubokura H
AD  - Department of Surgery II, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 
      113-8603, Japan.
FAU - Tenjin, T
AU  - Tenjin T
FAU - Akiyama, H
AU  - Akiyama H
FAU - Koizumi, K
AU  - Koizumi K
FAU - Nishimura, H
AU  - Nishimura H
FAU - Yamamoto, M
AU  - Yamamoto M
FAU - Tanaka, S
AU  - Tanaka S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Japan
TA  - Ann Thorac Cardiovasc Surg
JT  - Annals of thoracic and cardiovascular surgery : official journal of the 
      Association of Thoracic and Cardiovascular Surgeons of Asia
JID - 9703158
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Non-Small-Cell Lung/diagnosis/*genetics/mortality
MH  - Chromosome Aberrations/*mortality/*physiology
MH  - Chromosome Disorders
MH  - Chromosomes, Human, Pair 8/*physiology
MH  - Female
MH  - Follow-Up Studies
MH  - Gene Amplification/physiology
MH  - Genes, myc/*physiology
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Lung Neoplasms/diagnosis/*genetics/mortality
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Prognosis
MH  - Survival Rate
EDAT- 2001/10/02 10:00
MHDA- 2001/10/26 10:01
CRDT- 2001/10/02 10:00
PHST- 2001/10/02 10:00 [pubmed]
PHST- 2001/10/26 10:01 [medline]
PHST- 2001/10/02 10:00 [entrez]
PST - ppublish
SO  - Ann Thorac Cardiovasc Surg. 2001 Aug;7(4):197-203.